Tongji-Ezhou Study (TJEZ)

Tongji-Ezhou Prospectively Cohort Study

Tongji-Ezhou study (TJEZ) is a prospective cohort study launched at 2013 in EZhou city, Hubei province, with the goal of recruiting and assessing 10,000 individuals and then following them for at least 2 decades. In addition, blood samples would be collected every 3-5 years among 6000 of them to investigate the nutritional biomarkers and potential determinants of chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease.

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Diseases; Obesity; Diabetes; Metabolic Syndrome; Risk Factor, Cardiovascular; Environmental Exposure; Nutritional and Metabolic Diseases
• Intervention / Treatment: Other: Dietary and environmental exposure (Observational study)

• Study Type: Observational
• Enrollment (Anticipated): 10000

Contacts and Locations

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Recruiting
      • Huazhong University of Science and Technology
      • Contact: Liegang Liu, PhD; Phone Number: +86-27-83650522; Email: liegangliu@gmail.com
      • Principal Investigator: Cheng Luo, PhD
      • Principal Investigator: Liangkai Chen, PhD
      • Principal Investigator: Zhou Li, PhD
      • Principal Investigator: Jiawei Yin, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Samples were collected at two medical centrals (retired employees at Egang hospital and working employees at Ezhou CDC). The Retirement Office of Egang hospital and Health checkup center of CDC provided a list of the individuals and invited them to participant in our study.

Description

Inclusion Criteria:

• (i) permanent residence in Ezhou district (minimum of 9 months); (ii) written informed consent; (iii) age ≥ 20 years old at the time of enrolling in the study.

Exclusion Criteria:

• (i) with chemotherapy or radiotherapy for cancer and other severe diseases.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Egang hospital physical examination center	Other: Dietary and environmental exposure (Observational study)
Ezhou CDC physical examination center	Other: Dietary and environmental exposure (Observational study)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of diabetes	Type 2 diabetes was diagnosed when FPG ≥ 7.0 mmol/L and/or OGTT2h ≥ 11.1 mmol/L, or using diabetic medication (self-report).	5 years
Incidence of metabolic syndrome	Metabolic syndrome is defined as using the updated National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans. These criteria require three or more of the following components: (1) central obesity (waist circumference of ≥90 cm for men or ≥80 cm for women), (2) triglycerides of ≥1.7 mmol/L, (3) HDL-C of <1.03 mmol/L for men or <1.30 mmol/L for women, (4) blood pressure of ≥130/85 mmHg or on medication for hypertension, and (5) fasting glucose of ≥5.6 mmol/L.	5 years
Diabetic complications	Development of diabetic complications	mean follow up of 10 years
Incidence of cardiovascular diseases	Cardiovascular death, stroke, myocardial infarction, heart failure	mean follow up of 10 years

Collaborators and Investigators

• Sponsor: Huazhong University of Science and Technology

Publications and helpful links

General Publications

• Sun T, Deng Y, Geng X, Fang Q, Li X, Chen L, Zhan M, Li D, Zhu K, Li H, Liu L. Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain Intake, Is Inversely Associated with Risk of Nonalcoholic Fatty Liver Disease in a Case-Control Study of Chinese Adults. J Nutr. 2022 Apr 1;152(4):1052-1058. doi: 10.1093/jn/nxab404.

Study record dates

Study Major Dates

• Study Start (Actual): April 16, 2013
• Primary Completion (Actual): January 31, 2019
• Study Completion (Anticipated): December 31, 2025

Study Registration Dates

• First Submitted: February 14, 2019
• First Submitted That Met QC Criteria: February 16, 2019
• First Posted (Actual): February 19, 2019

Study Record Updates

• Last Update Posted (Actual): February 19, 2019
• Last Update Submitted That Met QC Criteria: February 16, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Insulin Resistance; Hyperinsulinism; Cardiovascular Diseases; Metabolic Syndrome; Metabolic Diseases
• Other Study ID Numbers: TJEZ2013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No